Antares Pharma, Inc. Signs ATD(TM) Gel Development Agreement With Dermatology Firm

EXTON, Pa., Nov. 10 /PRNewswire-FirstCall/ -- Antares Pharma, Inc. today announced that it has signed a feasibility development agreement with a firm focused on treating dermatological conditions and diseases. Under the agreement, Antares intends to apply its advanced transdermal delivery (ATD(TM)) gel platform to formulate an active compound contained in a topical skin product for dermal action. Antares expects to recognize research and development revenue from this phase of work, which is slated to be completed before the end of this year. Clinical supply and commercialization agreements are also anticipated upon successful completion of the initial phase of this program.

Antares' patent-protected ATD(TM) gel technology platform has been clinically and commercially validated for the systemic delivery of a variety of compounds. In addition, the development of modified gel systems for non-systemic, dermal delivery has been achieved. Loading level of drug in the ATD(TM) platform can be the same or higher than in conventional transdermal systems, be sustained for 24 hours after once daily application, and be accurately delivered via metered dose pump or unit dose sachet packaging. The cosmetic quality is superior, as ATD(TM) gels are both transparent and non-staining. There is also low potential for irritation because typically product formulations fully disappear within two to three minutes. More than one active compound may be delivered simultaneously, each at a different concentration, such that the permeation profile of each agent is optimally maintained.

James Hattersley, Vice President of Corporate Business Development at Antares Pharma, said, "We are pleased to initiate this collaboration, and look forward to designing an important new prescription dermatological product. We believe Antares' ATD(TM) technology is ideally suited for the molecule selected by our partner especially as it relates to its product commercialization strategy."

Jack E. Stover, President and CEO of Antares Pharma, said, "This agreement is another important milestone in the development and further validation of our ATD(TM) platform. We believe that the ATD(TM) system offers compelling benefits to patients in comparison to many other drug delivery dosage forms, differentiating and adding value to transdermally administered pharmaceutical products."

About Antares Pharma

Antares Pharma is a specialized pharma product development company with patented drug delivery systems and injectable device engineering capabilities. Antares' current technology platforms include its ATD(TM) Advanced Transdermal Delivery system, Easy Tec(TM) oral fast-melt technology, and subcutaneous injection technology platforms including both Vibex(TM) disposable mini-needle injection device and Valeo(TM) / Vision(R) reusable needle-free injection devices. Antares Pharma is committed to leveraging its multiple drug delivery platforms to add value to existing drugs and to create new pharmaceutical products and injectable devices. Overall, Antares believes its product pipeline will address unmet medical needs by reducing side effect profiles, improving safety, increasing effectiveness, and improving patient compliance and convenience.

Antares has active partnering programs with several pharmaceutical and distribution companies for a number of indications and applications, including diabetes, growth disorders, obesity, female sexual dysfunction and other hormone therapy. Its needle-free injector system is distributed in more than 30 countries for the administration of insulin and is marketed for use with human growth hormone through licensees in most major regions of the world. Licensees also market an ibuprofen gel in several major European countries. In addition, Antares Pharma is undertaking development or is conducting research on several product opportunities that it expects will form the basis of its specialized pharma program.

Antares Pharma has corporate headquarters in Exton, Pennsylvania, with subsidiaries performing research, development, manufacturing and product commercialization activities in Minneapolis, Minnesota and Basel, Switzerland.

Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The Company cautions readers that forward-looking statements are subject to certain risks and uncertainties, which could cause actual results to differ materially and which are identified from time to time in the Company's reports filed with the U.S. Securities and Exchange Commission. Antares Pharma claims the protection of the Safe Harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

For more information, please contact: Steve Chizzik / Ira Weingarten, Equity Communications: 973.912.0980 Jack E. Stover, President and CEO: 610.458.6200 Lawrence M. Christian, CFO and Vice President, Finance: 610.458.6200

Additional information is available online at http://www.antarespharma.com and http://www.mediject.com. Information included on the Company's websites is not incorporated herein by reference or otherwise.

Antares Pharma, Inc.

CONTACT: Steve Chizzik / Ira Weingarten, Equity Communications,+1-973-912-0980, or Jack E. Stover, President and CEO, Antares Pharma,+1-610-458-6200, or Lawrence M. Christian, CFO and Vice President, Finance,Antares Pharma, +1-610-458-6200

MORE ON THIS TOPIC